Could a drug combo free kidney transplant patients from lifelong pills?
NCT ID NCT04803058
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether a drug called TCD601 (siplizumab), combined with donor bone marrow cells and mild chemotherapy, can train the immune system to accept a new kidney without needing lifelong anti-rejection drugs. The trial involves 18 adults receiving a kidney from a living donor. The main goal is to see if participants can safely stop all immunosuppression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Siplizumab (TCD601) combined with donor bone marrow cells and chemotherapy drugs (fludarabine and cyclophosphamide)
What this could lead to
If it works, this could allow kidney transplant recipients to stop taking lifelong anti-rejection medications, reducing side effects and improving quality of life.
What could go wrong
This is a small, early-phase trial with only 18 participants. The approach is complex and carries risks from the chemotherapy and potential rejection. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Samsung Medical University
Seoul, South Korea